Lemtrada™ (alemtuzumab) for multiple sclerosis

Sanofi and its subsidiary Genzyme announced positive interim results from the second year of the extension study of Lemtrada™ (alemtuzumab) for multiple sclerosis

In approximately 70 percent of patients, disability scores improved or remained stable for an additional two years beyond the two-year…

10 years ago